5% Off
Topoxin100 mg/5 m
Beacon Pharmaceuticals PLC
৳380.00
Add to cart
Generic medicine
Etoposide: Brands, Price & Uses in Bangladesh
Etoposide is a cytotoxic chemotherapy agent used, always as part of physician-supervised combination regimens and more.
About Etoposide
Indications of Etoposide
Etoposide is a cytotoxic chemotherapy agent used, always as part of physician-supervised combination regimens, for the following malignancies:
FDA-approved indications (used in combination with other approved chemotherapeutic agents)
- Refractory testicular tumors — in patients who have already received appropriate surgical, chemotherapeutic, and radiotherapeutic treatment.
- Small cell lung cancer (SCLC) — as first-line combination therapy with a platinum agent (e.g., cisplatin or carboplatin).
Guideline-supported / widely accepted uses (may be considered off-label but standard of care)
- Hodgkin lymphoma and non-Hodgkin lymphoma (as part of multi-agent regimens).
- Acute myeloid leukemia (AML), particularly in relapsed/refractory or transplant-conditioning settings.
- Ewing sarcoma and neuroblastoma in pediatric oncology protocols.
- Gestational trophoblastic neoplasia.
- Conditioning regimens prior to autologous/allogeneic stem cell transplantation.
- Hemophagocytic lymphohistiocytosis (HLH), used per established HLH treatment protocols.
Etoposide must always be prescribed and administered by, or under the direct supervision of, a qualified oncologist experienced in the use of cancer chemotherapeutic agents. Etoposide is not indicated for any non-oncologic condition.
Dosage & Administration of Etoposide
Etoposide dosing is always determined by the treating oncologist according to the specific combination protocol, body surface area (BSA),and patient tolerance. The following are representative regimens; actual prescribed doses may vary by institutional protocol.
| Indication | Typical adult IV dose | Typical cycle pattern |
|---|---|---|
| Testicular cancer (combination therapy) | 50–100 mg/m² IV on days 1–5, or 100 mg/m² on days 1, 3, and 5 | Repeated every 3–4 weeks per protocol (e.g., BEP regimen) |
| Small cell lung cancer (combination with platinum agent) | 35 mg/m² IV daily for 4 days, or 50 mg/m² IV daily for 5 days | Repeated every 3–4 weeks |
| Lymphoma / AML / HLH / other protocol-based uses | Per specific published multi-agent protocol | As defined by protocol |
Renal impairment
- Creatinine clearance 15–50 mL/min: reduce dose to approximately 75% of the standard dose.
- Creatinine clearance below 15 mL/min: further dose reduction should be considered; use with caution and close monitoring.
Hepatic impairment
- Dose reduction is recommended in patients with elevated bilirubin; Etoposide should be used cautiously or withheld if bilirubin or transaminases are significantly elevated, per institutional protocol.
Administration
Etoposide injection must be diluted per manufacturer instructions and given as a slow intravenous infusion (typically over 30–60 minutes)to reduce the risk of hypotension and infusion-related reactions. Rapid IV administration must be avoided. See "Administration"section for further detail.
Side Effects of Etoposide
Side effects of Etoposide range from very common and expected (requiring monitoring) to rare but serious.
Very common / common
- Myelosuppression — leukopenia, neutropenia, thrombocytopenia, and anemia (dose-limiting; usually reversible and nadir around days 7–14).
- Alopecia (hair loss), usually reversible after treatment ends.
- Nausea and vomiting.
- Mucositis / stomatitis, diarrhea, loss of appetite.
- Fatigue, transient elevation of liver enzymes.
Less common / serious
- Anaphylactic-like reactions during infusion — hypotension, bronchospasm, dyspnea, facial or tongue swelling, flushing, chills, fever (see Precautions and Warnings).
- Peripheral neuropathy.
- Secondary leukemia (treatment-related acute myeloid leukemia), a recognized long-term risk with cumulative Etoposide exposure, especially in combination regimens.
- Hepatotoxicity.
- Local irritation or tissue injury with extravasation.
Patients should promptly report fever, unusual bruising/bleeding, severe mouth sores, breathing difficulty, or signs of infection to their oncology team.
Contraindications of Etoposide
Etoposide is contraindicated in patients with:
- Known hypersensitivity to Etoposide, etoposide phosphate, podophyllotoxin derivatives, or any component of the formulation.
- Severe, pre-existing bone marrow suppression (severe baseline neutropenia or thrombocytopenia), unless as part of a deliberate myeloablative transplant-conditioning protocol under specialist supervision.
Etoposide should not be administered to patients with a history of severe anaphylactic-like reactions to Etoposide or related compounds.
Frequently Asked Questions about Etoposide
What is Etoposide used for?
Etoposide is a chemotherapy medicine used, always in combination with other anticancer drugs and under oncologist supervision, to treat certain cancers including testicular cancer and small cell lung cancer, and is also commonly used in protocols for lymphomas, leukemia, and some other malignancies. It works by damaging the DNA of rapidly dividing cancer cells.
How is Etoposide given?
Etoposide is usually given as a slow intravenous infusion in a hospital or specialized cancer treatment center, typically over 30 to 60 minutes, following dilution as prepared by trained staff. In some cases, an oral capsule form of Etoposide may be prescribed instead; if so, it should be taken exactly as directed by the treating physician.
What are the most important side effects of Etoposide to watch for?
The most important effect of Etoposide is severe suppression of bone marrow function, which lowers white blood cells, platelets, and red blood cells and increases the risk of infection, bleeding, and anemia. Other common effects include hair loss, nausea, vomiting, and mouth sores. Rarely, Etoposide infusion can cause an anaphylactic-like reaction with low blood pressure, wheezing, or swelling of the face/tongue — patients are monitored closely during infusion for this reason. Report fever, unusual bruising or bleeding, or breathing difficulty to your care team immediately.
Can Etoposide be used during pregnancy or breastfeeding?
No, Etoposide should be strictly avoided during pregnancy because it can cause serious harm to a developing baby, and it is not recommended during breastfeeding because of its cytotoxic effects. Anyone who is pregnant, planning pregnancy, or breastfeeding must inform their oncologist before starting Etoposide, and effective contraception is generally advised during and after treatment as directed by the treating physician.
Who should not receive Etoposide?
Etoposide should not be given to anyone with a known allergy to Etoposide, etoposide phosphate, or related podophyllotoxin compounds, or to patients with severe pre-existing bone marrow suppression outside of a specifically planned transplant-conditioning protocol. Your oncologist will review your full medical history, blood counts, and organ function before prescribing Etoposide.
What happens if a dose of Etoposide is missed or an overdose occurs?
Etoposide treatment schedules are individually planned by the oncology team, so any missed or delayed dose should be reported to them promptly rather than adjusted independently. If an overdose of Etoposide is suspected, this is a medical emergency — seek immediate medical attention or contact emergency services or a poison control center right away, as overdose can cause severe, potentially life-threatening suppression of blood cell production and other serious effects.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.